Latest Breaking News On - Sharon moe - Page 1 : comparemela.com

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

/PRNewswire/ Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative.

United statesMike raabSharon moeFosun pharmaIndiana university school of medicineRenal drugs advisory committeeDrug administrationArdelyx incAdvisory committeeOffice of new drugsPrnewswire ardelyx incNew drugsIndiana university schoolDrug evaluationComplete response letterKyowa kirin

Ardelyx (ARDX) Announces 9:4 FDA Vote AdCom Vote Favoring XPHOZAH

Ardelyx (ARDX) Announces 9:4 FDA Vote AdCom Vote Favoring XPHOZAH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMike raabSharon moeFosun pharmaExchange commission onIndiana university school of medicineRenal drugs advisory committeeDrug administrationArdelyx incAdvisory committeeExchange commissionOffice of new drugsIndiana university schoolNew drugsDrug evaluationComplete response letter

Ardelyx Inc s shares jump 43% as US Food and Drug Administration (FDA) advisory panel backs Xphozah

Ardelyx Inc s shares jump 43% as US Food and Drug Administration (FDA) advisory panel backs Xphozah
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Mike raabSharon moeIndiana university school of medicineDrug administrationArdelyx incIndiana university school

Why some hospitals have stopped using race-based calculations for kidney disease

Health care providers often rely on digital tools to inform treatment decisions. A growing number of hospitals are moving away from factoring race into kidney disease calculations, after recognizing Black patients could be at a disadvantage.

United statesSharon moeDavid jonesAmerican association of nephrologyHarvard medical schoolIu healthNational kidney foundationIndiana university healthCrystal mooreFarah yousrySide effects publicAmerican associationUniversity healthIndiana universityNew england journal

Why some hospitals have stopped using race-based calculations for kidney disease

Studies show Black patients are more likely to have kidney failure than white patients. They also make it onto transplant lists later, and once they’re on the list, they wait longer to get a kidney.

United statesSharon moeDavid jonesAmerican association of nephrologyHarvard medical schoolIu healthNational kidney foundationIndiana university healthCrystal mooreFarah yousrySide effects publicAmerican associationUniversity healthIndiana universityNew england journal